Aptose Biosciences Inc.

APS

CA03835T3091

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 01:29:59 16/07/2024 am IST			5-day change	1st Jan Change
0.97 ^CAD	+3.19%		-5.83%	-71.04%

18/06	Transcript : Aptose Biosciences Inc. - Shareholder/Analyst Call
14/06	Aptose Biosciences Inc. Presents Tuspetinib Clinical and Preclinical Findings At European Hematology Association 2024 Hybrid Congress	CI

APTOSE BIOSCIENCES INC. : Financial Statements and Exhibits (form 8-K)

January 06, 2023 at 07:21 pm IST

Item 9.01. Financial Statements and Exhibits.





  99.1        Aptose Corporate Presentation - January 2023
104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

Latest news about Aptose Biosciences Inc.

Transcript : Aptose Biosciences Inc. - Shareholder/Analyst Call	18/06
Aptose Biosciences Inc. Presents Tuspetinib Clinical and Preclinical Findings At European Hematology Association 2024 Hybrid Congress	14/06	CI
HC Wainwright Adjusts Price Target on Aptose Biosciences to $7 From $23, Maintains Buy Rating	11/06	MT
Aptose Closes U$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	04/06	MT
Aptose Biosciences Down 14% In US Premarket As Plans to Raise Near $4.4 Million Via Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	31/05	MT
Aptose Biosciences Brief: Announcing US$4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	31/05	MT
Transcript : Aptose Biosciences Inc., Q1 2024 Earnings Call, May 14, 2024	15/05
Aptose Biosciences Q1 Net Loss Falls, on Lower Expenses	15/05	MT
Aptose Biosciences Brief: Also Notes TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML	15/05	MT
Aptose Biosciences Brief: Notes TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to FDA During Q1 and is Now Being Activated at Clinical Sites	15/05	MT
Aptose Biosciences Brief: Q1 Net Loss per share, Basic and diluted US$(0.73)	15/05	MT
Certain Warrants of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04	CI
Certain Common Shares of Aptose Biosciences Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	25/04	CI
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Transcript : Aptose Biosciences Inc., Q4 2023 Earnings Call, Mar 26, 2024	27/03
Aptose Biosciences Up 3% After Hours as its 2023 Loss Widens on Higher R&D Spending	27/03	MT
Aptose Biosciences Brief: Says Luxeptinib G3 Formulation Achieved "Desired Levels and Positions for Future Trials"	27/03	MT
Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations with Excellent Safety Profile"	27/03	MT
Aptose Biosciences Brief: Q4 Basic and diluted loss per Common Share US$7.58	27/03	MT
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
North American Morning Briefing : Markets Steady -2-	26/03	DJ
North American Morning Briefing : Stock Futures -2-	19/03	DJ
Top Premarket Gainers	02/02	MT
Aptose Biosciences Down 3% After Hours as it Raises US$13.7 Million in a Bought-Deal Offering, Private Placement	01/02	MT
Aptose Biosciences Raises US$13.7 Million in a Bought-Deal Offering of Share Units and Concurrent Private Placement	01/02	MT

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.97

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
APTOSE BIOSCIENCES INC.	-71.04%	15.59M
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+44.53%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research